Cited by 227Diabetes Treatment and ManagementDiabetes Management and ResearchIon Transport and Channel Regulation

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Mudaliar, Sunder, Polidori, David, Zambrowicz, Brian, Henry, Robert R.·2015·Diabetes Care

Open this paper in CoChat — free account

Abstract

Type 2 diabetes is a chronic disease with disabling micro- and macrovascular complications that lead to excessive morbidity and premature mortality. It affects hundreds of millions of people and imposes an undue economic burden on populations across the world. Although insulin resistance and insulin secretory defects play a major role in the pathogenesis of hyperglycemia, several other metabolic defects contribute to the initiation/worsening of the diabetic state. Prominent among these is increased renal glucose reabsorption, which is maladaptive in patients with diabetes. Instead of an increase in renal glucose excretion, which could ameliorate hyperglycemia, there is an increase in renal glucose reabsorption, which helps sustain hyperglycemia in patients with diabetes. The sodium-glucose cotransporter (SGLT) 2 inhibitors are novel antidiabetes agents that inhibit renal glucose reabsorption and promote glucosuria, thereby leading to reductions in plasma glucose concentrations. In this article, we review the long journey from the discovery of the glucosuric agent phlorizin in the bark of the apple tree through the animal and human studies that led to the development of the current generation of SGLT2 inhibitors.

Integrity signals

Registry

Crossref · 10.2337/dc15-0642

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Biology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 5×
“EGP increased after a single dose of canagliflozin in healthy subjects (14) and increased by ;17–25% after single and multiple doses of empagliflozin and dapagliflozin in patients with T2D (38,41).”
BackgroundInfluential
Expression cloning and cDNA sequencing of the Na+/glucose co-transporter
Hediger, M. A., Coady, M. J., Ikeda, T. S., & Wright, E. M. (1987) · Nature · doi:10.1038/330379a0 · Cited by 1,004
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats.
Rossetti, L., Smith, D. J., Shulman, G. I., Papachristou, D. N., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 824
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 2×
“EGP increased after a single dose of canagliflozin in healthy subjects (14) and increased by ;17–25% after single and multiple doses of empagliflozin and dapagliflozin in patients with T2D (38,41).”
Background
Glucose Transporters in Human Renal Proximal Tubular Cells Isolated From the Urine of Patients With Non–Insulin-Dependent Diabetes
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 787

Show all 60 references

Sorted by citations

Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Puchalska, P., & Crawford, P. A. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.022 · Cited by 1,682
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Erondu, N., Shaw, W., Barrett, T. D., Weidner-Wells, M., Deng, H., Matthews, D. R., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30141-4 · Cited by 637
Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME Study? A unifying hypothesis
Mudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571
Self-citation
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K. J., & Newsome, P. N. (2018) · Hepatology · doi:10.1002/hep.30429 · Cited by 552
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Ghezzi, C., Loo, D. D. F., & Wright, E. M. (2018) · Diabetologia · doi:10.1007/s00125-018-4656-5 · Cited by 349
Sodium-Glucose Co-transporters and Their Inhibition: Clinical Physiology
Ferrannini, E. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.011 · Cited by 354
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
Wang, X. X., Levi, J., Luo, Y., Myakala, K., Herman‐Edelstein, M., Qiu, L., Wang, D., Peng, Y., Grenz, A., Lucia, S. M., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.779520 · Cited by 307
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Byrne, N. J., Matsumura, N., Maayah, Z. H., Ferdaoussi, M., Takahara, S., Darwesh, A. M., Levasseur, J. L., Jahng, J. W. S., Vos, D. Y., Parajuli, N., et al. (2020) · Circulation Heart Failure · doi:10.1161/circheartfailure.119.006277 · Cited by 265
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Bailey, C. J., Day, C., & Bellary, S. (2022) · Current Diabetes Reports · doi:10.1007/s11892-021-01442-z · Cited by 273
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives
Qiu, H., Novikov, A., & Vallon, V. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2886 · Cited by 227
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
Januzzi, J. L., Butler, J., Jarolı́m, P., Sattar, N. A., Vijapurkar, U., Desai, M. G., & Davies, M. J. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.06.016 · Cited by 215
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Cusi, K., Bril, F., Barb, D., Polidori, D., Sha, S., Ghosh, A., Farrell, K., Sunny, N. E., Kalavalapalli, S., Pettus, J., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13584 · Cited by 204
Self-citation
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 191
The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer
Koepsell, H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.10.017 · Cited by 190
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Bailey, C. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13670 · Cited by 187
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 166
Nonalcoholic Fatty Liver Disease
Bril, F., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.005 · Cited by 158
Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus
Tanaka, H., Takano, K., Iijima, H., Kubo, H., Maruyama, N., Hashimoto, T., Arakawa, K., Togo, M., Inagaki, N., & Kaku, K. (2017) · Advances in Therapy · doi:10.1007/s12325-016-0457-8 · Cited by 140
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions
Cusi, K. J. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 141
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
Choi, C. (2016) · Molecules · doi:10.3390/molecules21091136 · Cited by 136
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 126
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study
Yuan, Ž., DeFalco, F., Ryan, P. B., Schuemie, M. J., Stang, P., Berlin, J. A., Desai, M. G., & Rosenthal, N. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13115 · Cited by 127
Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
Naznin, F., Sakoda, H., Okada, T., Tsubouchi, H., Waise, T. M. Z., Arakawa, K., & Nakazato, M. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.028 · Cited by 114
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand?
Tomah, S., Alkhouri, N., & Hamdy, O. (2020) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-020-00097-1 · Cited by 122
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists
Wilcox, T., Block, C. E. M. D., Schwartzbard, A. Z., & Newman, J. D. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.02.056 · Cited by 124
Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
Oh, C., Cho, S., Jang, J., Kim, H., Chun, S., Choi, M., Park, S., & Ko, Y. (2019) · Korean Circulation Journal · doi:10.4070/kcj.2019.0180 · Cited by 109
SGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications
Palma, R., Pronio, A., Romeo, M., Scognamiglio, F., Ventriglia, L., Ormando, V. M., Lamazza, A., Pontone, S., Federico, A., & Dallio, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133649 · Cited by 113
Intestinal SGLT1 in metabolic health and disease
Lehmann, A., & Hornby, P. J. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00068.2016 · Cited by 104
The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non‐alcoholic fatty liver disease
Phrueksotsai, S., Pinyopornpanish, K., Euathrongchit, J., Leerapun, A., Phrommintikul, A., Buranapin, S., Chattipakorn, N., & Thongsawat, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15580 · Cited by 104
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
Kaplan, A., Abidi, E., EL‐Yazbi, A. F., Eid, A. H., Booz, G. W., & Zouein, F. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9665-9 · Cited by 108
Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)
Kim, J., Zhang, J., Cha, Y., Kolitz, S. E., Funt, J. M., Escalante-Chong, R., Barrett, S., Kusko, R. L., Zeskind, B., & Kaufman, H. L. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02430-9 · Cited by 106
Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
Januzzi, J. L., Xu, J., Li, J., Shaw, W., Oh, R., Pfeifer, M., Butler, J., Sattar, N., Mahaffey, K. W., Neal, B., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.004 · Cited by 97
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 97
Updates on Managing Type 2 Diabetes Mellitus with Natural Products: Towards Antidiabetic Drug Development
Alam, F., Islam, M. A., Kamal, M. A., & Gan, S. H. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160813222436 · Cited by 90
Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors
Blaschek, W. (2017) · Planta Medica · doi:10.1055/s-0043-106050 · Cited by 88
Crosstalk between gut microbiota and antidiabetic drug action
Kyriachenko, Y., Falalyeyeva, T. M., Korotkyi, O., Molochek, N., & Kobyliak, N. M. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i3.154 · Cited by 82
Inhibition of sodium–glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
Baker, H. E., Kiel, A. M., Luebbe, S. T., Simon, B. R., Earl, C. C., Regmi, A., Roell, W. C., Mather, K. J., Tune, J. D., & Goodwill, A. G. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0733-2 · Cited by 77
Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
Xing, B., Zhao, Y., Dong, B., Zhou, Y., Lv, W., & Zhao, W. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13237 · Cited by 77
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus
Inagaki, N., Harashima, S., Maruyama, N., Kawaguchi, Y., Goda, M., & Iijima, H. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0407-4 · Cited by 72
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
Hwang, I., Cho, G., Yoon, Y. E., Park, J. J., Park, J., Lee, S., Kim, H., Kim, Y.-J., & Sohn, D. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01042-3 · Cited by 68
Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action
Al-Nour, M. Y., Ibrahim, M. M., & Elsaman, T. (2019) · Current Pharmacology Reports · doi:10.1007/s40495-019-00181-w · Cited by 71
Dapagliflozin Reduces Apoptosis of Diabetic Retina and Human Retinal Microvascular Endothelial Cells Through ERK1/2/cPLA2/AA/ROS Pathway Independent of Hypoglycemic
Hu, Y., Xu, Q., Li, H., Meng, Z., Hao, M., Ma, X., Lin, W., & Kuang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827896 · Cited by 69
SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study
Sardu, C., Massetti, M., Rambaldi, P., Gatta, G., Cappabianca, S., Sasso, F. C., Santamaria, M., Volpicelli, M., Ducceschi, V., Signoriello, G., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155243 · Cited by 65
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes
Goodwin, N. C., Ding, Z., Harrison, B. A., Strobel, E. D., Harris, A. L., Smith, M. G., Thompson, A. Y., Xiong, W., Mseeh, F., Bruce, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01541 · Cited by 66
Intra‐ and inter‐subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co‐transporter 2 inhibitor canagliflozin
Polidori, D., Iijima, H., Goda, M., Maruyama, N., Inagaki, N., & Crawford, P. A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13224 · Cited by 65
Self-citation
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
Rodbard, H. W., Seufert, J., Aggarwal, N., Cao, A., Fung, A., Pfeifer, M. A., & Alba, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12684 · Cited by 64
Improving glycaemic control in type 2 diabetes: S timulate insulin secretion or provide beta‐cell rest?
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 63
Sotagliflozin: First Global Approval
Markham, A., & Keam, S. J. (2019) · Drugs · doi:10.1007/s40265-019-01146-5 · Cited by 64
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Chen, L., LaRocque, L. M., Efe, O., Wang, J., Sands, J. M., & Klein, J. D. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.08.015 · Cited by 59
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
Distribution of glucose transporters in renal diseases
Szablewski, L. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0371-7 · Cited by 59
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
Powell, D. R., Zambrowicz, B., Morrow, L., Beysen, C., Hompesch, M., Turner, S., Hellerstein, M. K., Banks, P. L., Strumph, P., & Lapuerta, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz258 · Cited by 60
Self-citation
Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Kramer, C. K., & Zinman, B. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-042017-094221 · Cited by 57
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 59
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus
Portillo-Sánchez, P., & Cusi, K. J. (2016) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-016-0027-7 · Cited by 57
A review of recent progress in improving the bioavailability of nutraceutical‐loaded emulsions after oral intake
Chen, X., Chen, Y., Liu, Y., Zou, L., McClements, D. J., & Liu, W. (2022) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.13017 · Cited by 54
Inhibitor binding mode and allosteric regulation of Na+-glucose symporters
Bisignano, P., Ghezzi, C., Jo, H., Polizzi, N. F., Althoff, T., Kalyanaraman, C., Friemann, R., Jacobson, M. P., Wright, E. M., & Grabe, M. (2018) · Nature Communications · doi:10.1038/s41467-018-07700-1 · Cited by 53
Flavonoid-rich extract of Chromolaena odorata modulate circulating GLP-1 in Wistar rats: computational evaluation of TGR5 involvement
Omotuyi, O. I., Nash, O., Inyang, O. K., Ogidigo, J. O., Enejoh, O. A., Okpalefe, O. A., & Hamada, T. (2018) · 3 Biotech · doi:10.1007/s13205-018-1138-x · Cited by 52
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Canagliflozin review – safety and efficacy profile in patients with T2DM
Jakher, H., Chang, T. I., Tan, M. J., & Mahaffey, K. W. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184437 · Cited by 51
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care
Danne, T., Biester, T., & Kordonouri, O. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0081 · Cited by 48
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?
Mazzotti, A., Caletti, M. T., Marchignoli, F., Forlani, G., & Marchesini, G. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2016.12.028 · Cited by 46
Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus
Koike, Y., Shirabe, S., Maeda, H., Yoshimoto, A., Arai, K., Kumakura, A., Hirao, K., & Terauchi, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.029 · Cited by 47
MASLD development: From molecular pathogenesis toward therapeutic strategies
Yang, Z., Zhao, J., Xie, K., Tang, C., Gan, C., & Gao, J. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003629 · Cited by 49
Efficacy and safety of tofogliflozin in J apanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy ( J‐STEP / INS ): Results of a 16‐week randomized, double‐blind, placebo‐controlled multicentre trial
Terauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12957 · Cited by 44
(‐)‐Epicatechin and the Colonic 2,3‐Dihydroxybenzoic Acid Metabolite Regulate Glucose Uptake, Glucose Production, and Improve Insulin Signaling in Renal NRK‐52E Cells
Álvarez‐Cilleros, D., Martín, M. Á., & Ramos, S. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700470 · Cited by 44
SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
Shao, S.-C., Kuo, L.-T., Chien, R.-N., Hung, M.-J., & Lai, E. C.-C. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001956 · Cited by 43
Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF‐A /caveolin‐1/ PV ‐1 signaling pathway
Locatelli, M., Zoja, C., Conti, S., Cerullo, D., Corna, D., Rottoli, D., Zanchi, C., Tomasoni, S., Remuzzi, G., & Benigni, A. (2022) · The Journal of Pathology · doi:10.1002/path.5862 · Cited by 44
Impact of SGLT-2 Inhibition on Cardiometabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome
Pruett, J. E., Fernandez, E. D. T., Everman, S. J., Vinson, R. M., Davenport, K., Logan, M. K., Ye, S. A., Romero, D. G., & Cardozo, L. L. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052576 · Cited by 43
Effects of sodium glucose co-transporter 2 inhibitors on the kidney
Rocha, N. D. A., Neeland, I. J., McCullough, P. A., Toto, R. D., & McGuire, D. K. (2018) · Diabetes and Vascular Disease Research · doi:10.1177/1479164118783756 · Cited by 41
Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus
Blevins, T., & Farooki, A. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2017.1256747 · Cited by 38
Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran, H., Cherney, D. Z. I., & Lovshin, J. A. (2017) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000343 · Cited by 37
Enterococcus faecalis YM0831 suppresses sucrose-induced hyperglycemia in a silkworm model and in humans
Matsumoto, Y., Ishii, M., Hasegawa, S., & Sekimizu, K. (2019) · Communications Biology · doi:10.1038/s42003-019-0407-5 · Cited by 36
Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
Yang, S., Liu, Y., Zhang, S., Wu, F., Liu, D., Wu, Q., Zheng, H., Fan, P., & Su, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1145587 · Cited by 40
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice
Powell, D. R., Smith, M. G., Doree, D. D., Harris, A. L., Greer, J., DaCosta, C. M., Thompson, A. Y., Jeter-Jones, S. L., Xiong, W., Carson, K. G., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240820 · Cited by 33
Self-citation
Effects of the sodium‐glucose cotransporter 2 ( SGLT 2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats
Hoenig, M. E., Clark, M., Schaeffer, D. J., & Reiche, D. (2017) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12467 · Cited by 34
Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
Posch, M. G., Walther, N., Ferrannini, E., Powell, D. R., Banks, P. L., Wason, S., & Dahmen, R. (2022) · Diabetes Care · doi:10.2337/dc21-2166 · Cited by 34
SGLT2 inhibitors across various patient populations in the era of precision medicine: the multidisciplinary team approach
McLean, P., Bennett, J., Woods, E. A., Chandrasekhar, S. A., Newman, N. A., Mohammad, Y., Khawaja, M., Rizwan, A. M., Siddiqui, R., Birnbaum, Y., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00068-z · Cited by 38
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
Alkhouri, N., Poordad, F. F., & Lawitz, E. (2018) · Hepatology Communications · doi:10.1002/hep4.1195 · Cited by 32
Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes
Chowdhury, M. K. H., Turner, N. A., Bentley, N. L., Das, A., Wu, L. E., Richani, D., Bustamante, S., Gilchrist, R. B., Morris, M. J., Shepherd, P. R., et al. (2017) · Scientific Reports · doi:10.1038/srep40159 · Cited by 32
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H. R., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N. C., Radvar, A. D., Majidi, Z., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3922 · Cited by 32
NASH: A glance at the landscape of pharmacological treatment.
Brodosi, L., Marchignoli, F., Petroni, M., & Marchesini, G. (2016) · Annals of Hepatology · doi:10.5604/16652681.1212318 · Cited by 30
Glucagon Levels During Short-Term SGLT2 Inhibition Are Largely Regulated by Glucose Changes in Patients With Type 2 Diabetes
Lundkvist, P., Pereira, M. J., Kamble, P. G., Katsogiannos, P., Langkilde, A. M., ESTERLINE, R. L., JOHNSSON, E. K., & Eriksson, J. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00969 · Cited by 31
Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents
Du, F., Hinke, S. A., Cavanaugh, C., Polidori, D., Wallace, N., Kirchner, T., Jennis, M., Lang, W., Kuo, G., Gaul, M. D., et al. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.248575 · Cited by 32
Self-citation
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 31
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data
Henney, A. E., Riley, D. R. J., Hydes, T., Anson, M., Ibarburu, G. H., Frost, F., Alam, U., & Cuthbertson, D. J. (2024) · Thorax · doi:10.1136/thorax-2024-221906 · Cited by 28
Inhibitory effects of Gymnema inodorum (Lour.) Decne leaf extracts and its triterpene saponin on carbohydrate digestion and intestinal glucose absorption
Srinuanchai, W., Nooin, R., Pitchakarn, P., Karinchai, J., Suttisansanee, U., Chansriniyom, C., Jarussophon, S., Temviriyanukul, P., & Nuchuchua, O. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113398 · Cited by 29
Process Development of Sotagliflozin, a Dual Inhibitor of Sodium–Glucose Cotransporter-1/2 for the Treatment of Diabetes
Zhao, M. M., Zhang, H., Iimura, S., Bednarz, M. S., Song, Q., Lim, N., Yan, J. R., Wu, W., Dai, K., Gu, X., et al. (2020) · Organic Process Research & Development · doi:10.1021/acs.oprd.0c00359 · Cited by 28
Hypoglycemic and hypolipidemic activities of phlorizin from Lithocarpus polystachyus Rehd in diabetes rats
Zhang, W., Chen, S., Fu, H., Shu, G., Tang, H., Zhao, X., Chen, Y., Huang, X., Zhao, L., Yin, L., et al. (2021) · Food Science & Nutrition · doi:10.1002/fsn3.2165 · Cited by 28
Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis
Gronda, E., Lopaschuk, G. D., Arduini, A., Santoro, A., Benincasa, G., Palazzuoli, A., Gabrielli, D., & Claudio Napoli, A. (2022) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2021-0399 · Cited by 30
Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis
Zafar, Y., Rashid, A. M., Siddiqi, A. K., Ellahi, A., Ahmed, A. B., Hussain, H. U., Ahmed, F., Menezes, R. G., Siddiqi, T. J., & Maniya, M. T. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101970 · Cited by 28
Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent glucose transporter 2 inhibitor canagliflozin in human intestines and renal tubules
Mori, K., Saito, R., Nakamaru, Y., Shimizu, M., & Yamazaki, H. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2040 · Cited by 28
SGLT-2 inhibitors: Their pleiotropic properties
Vallianou, N. G., Geladari, E. V., & Kazazis, C. E. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.12.003 · Cited by 28
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
Cavaiola, T. S., & Pettus, J. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s154602 · Cited by 27
Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
Kim, H. M., Hwang, I., Choi, W., Yoon, Y. E., & Cho, G. (2021) · Scientific Reports · doi:10.1038/s41598-021-01759-5 · Cited by 27

Authors: Mudaliar, S., Polidori, D., Zambrowicz, B., & Henry, R. R.
Affiliations: University of California San Diego (US)
Janssen Research & Development (United States) (US)
Regeneron (United States) (US)
Corresponding author: Mudaliar, Sunder
ORCID: Mudaliar, Sunder
Polidori, David
Zambrowicz, Brian
Henry, Robert R.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2015-11-19
Volume: 38
Issue: 12
Pages: 2344-2353
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc15-0642
OpenAlex: W2175616918
Cited by: 225
References: 60
Citations by year: 2026: 5 · 2025: 19 · 2024: 14 · 2023: 18 · 2022: 21 · 2021: 21 · 2020: 23 · 2019: 17 · 2018: 27 · 2017: 32 · 2016: 28
FWCI: 4.36
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
Keywords: SGLT2 inhibitors, sodium-glucose cotransporter, renal glucose reabsorption, intestinal glucose transport, type 2 diabetes, hyperglycemia, glycosuria, phloridzin, antidiabetic drug development, history of drug discovery
MeSH terms: Sodium-Glucose Transporter 2 Inhibitors, Animals, Biological Transport, Diabetes Mellitus, Type 2, Glucose, Glycosuria, Humans, Hypoglycemic Agents, Insulin Resistance, Intestinal Mucosa, Kidney, Phlorhizin, Sodium-Glucose Transport Proteins, Sodium-Glucose Transporter 2, Renal Elimination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sodium–Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks